Objective To explore the effect of Qiangjin Zhuanggu prescription on bone mineral density(BMD),bone metabolism and balance ability in patients with postmenopausal osteoporosis(PMOP)of the liver and kidney deficiency type.Methods A total of 60 patients with PMOP from June 2022 to June 2023 were randomly divided into a control group and an observation group,with 30 patients in each group.The control group received treatment with calcium carbonate D3 chewable tablets and calcitriol capsules,while the observation group received the same treatment plus Qiangjin Zhuanggu prescription. The bone density,pain scores(VAS),balance ability(OLST),and bone metabolism indicators(serum CTX,BGP levels)of the two groups before and after treatment were collected and compared.Results There was no significant difference in hip BMD between the two groups before treatment(P>0.05). The hip bone density of the observation group was significantly higher than that of the control group after treatment(P<0.05).Before treatment,there was no significant difference in VAS scores between the two groups(P>0.05).After treatment,VAS scores in both groups decreased,and the observation group's VAS scores were lower than those of the control group(P<0.05).Before treatment,there was no significant difference in OLST times between the two groups(P>0.05).After treatment,the OLST times in the observation group significantly increased and were higher than those of the control group(P<0.05).Before treatment,there was no significant difference in serum CTX,BGP levels between the two groups(P>0.05).After treatment,the serum CTX,BGP levels in the observation group decreased and were lower than those of the control group(P<0.05).Conclusion Qiangjin zhuanggu prescription can improve abnormal bone metabolism,increase bone mineral density and balance ability.Qiangjin zhuanggu prescription can relieve pain in PMOP patients with deficiency of liver and kidney.
万方数据
维普
